XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue recognition and accounts receivable (Tables)
9 Months Ended
Sep. 30, 2024
Revenue Recognition And Accounts Receivable [Abstract]  
Schedule of Net Sales by Product Category by Reporting Segment

The table below presents net sales by product category by reporting segment:

 

 

 

Three Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2024

 

 

2023

 

 

Change

 

Bone Growth Therapies

 

$

57,925

 

 

$

53,359

 

 

 

8.6

%

Spinal Implants, Biologics, and Enabling Technologies

 

 

108,179

 

 

 

100,993

 

 

 

7.1

%

Global Spine

 

 

166,104

 

 

 

154,352

 

 

 

7.6

%

Global Orthopedics

 

 

30,502

 

 

 

29,654

 

 

 

2.9

%

Net sales

 

$

196,606

 

 

$

184,006

 

 

 

6.8

%

 

 

 

Nine Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2024

 

 

2023

 

 

Change

 

Bone Growth Therapies

 

$

169,537

 

 

$

153,735

 

 

 

10.3

%

Spinal Implants, Biologics, and Enabling Technologies

 

 

325,894

 

 

 

307,799

 

 

 

5.9

%

Global Spine

 

 

495,431

 

 

 

461,534

 

 

 

7.3

%

Global Orthopedics

 

 

88,403

 

 

 

84,692

 

 

 

4.4

%

Net sales

 

$

583,834

 

 

$

546,226

 

 

 

6.9

%

Schedule of Components Net Sales

The table below presents product sales and marketing service fees, which are both components of net sales:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Product sales

 

$

184,040

 

 

$

170,666

 

 

$

545,288

 

 

$

506,992

 

Marketing service fees

 

 

12,566

 

 

 

13,340

 

 

 

38,546

 

 

 

39,234

 

Net sales

 

$

196,606

 

 

$

184,006

 

 

$

583,834

 

 

$

546,226

 

Allowances for Expected Credit Losses

The following table provides a detail of changes in the Company’s allowance for expected credit losses for the three and nine months ended September 30, 2024 and 2023:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Allowance for expected credit losses beginning balance

 

$

8,368

 

 

$

7,015

 

 

$

7,130

 

 

$

6,419

 

Addition resulting from the Merger with SeaSpine

 

 

 

 

 

 

 

 

 

 

 

137

 

Current period provision for expected credit losses

 

 

486

 

 

 

415

 

 

 

2,059

 

 

 

905

 

Write-offs charged against the allowance and other

 

 

(1,118

)

 

 

(214

)

 

 

(1,321

)

 

 

(334

)

Effect of changes in foreign exchange rates

 

 

142

 

 

 

(126

)

 

 

10

 

 

 

(37

)

Allowance for expected credit losses ending balance

 

$

7,878

 

 

$

7,090

 

 

$

7,878

 

 

$

7,090